Key facts
- This page summarizes Bradley J. Bolzon PhD's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2022, 17:35.
Bradley J. Bolzon PhD - 09 Jun 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Director
- Issuer ticker
- CRSP
- Reported as of
- 09 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2022, 17:35:09 UTC
- Prior SEC filing
- 21 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bradley J. Bolzon PhD filed Form 4 for CRISPR Therapeutics AG (CRSP) on 10 Jun 2022.
Change
- Previous filing in this sequence was filed on 21 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,000
- Change %
- Price
- $0.000000
- Shares after
- 12,000
- Date
- 09 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 12,000
- Exercise price
- $71.70
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
SEC remarks
Exhibit 24 - Power of Attorney